0001104659-26-048997
SEC filingArmata Pharmaceuticals appointed Dr. Daniel Gilmer to its Board of Directors, effective April 24, 2026, with standard non-management director compensation.
Armata Pharmaceuticals appointed Dr. Daniel Gilmer to its Board of Directors effective April 24, 2026. Dr. Gilmer is Senior Director, Commercial Quality U.S. Team Lead at Pfizer, with experience launching PAXLOVID and developing anti-infectives. His appointment brings commercial and regulatory expertise as Armata advances its bacteriophage pipeline. Compensation includes a $40,000 annual cash retainer and an expected option award for 51,280 shares vesting over three years. The filing also includes a press release (Exhibit 99.1) furnished under Item 7.01.